| Literature DB >> 31608550 |
Andrew Crofts1, Michael E Kelly2, Claire L Gibson3.
Abstract
Disability and effectiveness of physical therapy are highly variable following ischemic stroke due to different brain regions being affected. Functional magnetic resonance imaging (fMRI) studies of patients in the months and years following stroke have given some insight into how the brain recovers lost functions. Initially, new pathways are recruited to compensate for the lost region, showing as a brighter blood oxygen-level-dependent (BOLD) signal over a larger area during a task than in healthy controls. Subsequently, activity is reduced to baseline levels as pathways become more efficient, mimicking the process of learning typically seen during development. Preclinical models of ischemic stroke aim to enhance understanding of the biology underlying recovery following stroke. However, the pattern of recruitment and focusing seen in humans has not been observed in preclinical fMRI studies that are highly variable methodologically. Resting-state fMRI studies show more consistency; however, there are still confounding factors to address. Anesthesia and method of stroke induction are the two main sources of variability in preclinical studies; improvements here can reduce variability and increase the intensity and reproducibility of the BOLD response detected by fMRI. Differences in task or stimulus and differences in analysis method also present a source of variability. This review compares clinical and preclinical fMRI studies of recovery following stroke and focuses on how refinement of preclinical models and MRI methods may obtain more representative fMRI data in relation to human studies.Entities:
Keywords: Stroke; imaging; plasticity; preclinical; recovery
Mesh:
Year: 2019 PMID: 31608550 PMCID: PMC7003729 DOI: 10.1111/jon.12668
Source DB: PubMed Journal: J Neuroimaging ISSN: 1051-2284 Impact factor: 2.486
Summary of Methods and Outcome Measures of Recent Preclinical fMRI Studies of Experimental Stroke in Rats’ Study
| Rat Strain/Sex/Age | Longitudinal? | Anesthetic | Stroke Model | Outcome Measures | |
|---|---|---|---|---|---|
| Dijkhuizen et al | Sprague‐Dawley, male, adult | No | Alpha‐chloralose | Permanent MCAO | Cerebral blood volume fMRI (3/14 days post‐MCAO), behavior, lesion volume. |
| Abo et al | Sprague‐Dawley, male, young adult | No | .5% Isoflurane, muscle relaxant | Photochemical | Cerebral blood volume fMRI (3 weeks poststroke, behavior). |
| Sauter et al | Fischer, male, not specified | No | 2% Isoflurane/Nitrous oxide | Permanent MCAO | CBF fMRI, lesion volume (1/2/5/12 days post‐MCAO), apparent diffusion coefficient (ADC). Placebo vs neuroprotection with isradipine. |
| DIjkhuizen et al | Sprague‐Dawley, male, adult | No | Alpha‐chloralose | 2 hour MCAO | CBV fMRI (1/3/14 days post‐MCAO), neurological score, lesion volume, ADC |
| Markus et al | Not specified, not specified, 25 months | No | Not specified | Permanent MCAO | CBV fMRI (8 weeks post‐MCAO), behavior, effect of novel therapeutic |
| Sicard et al | Sprague‐Dawley, male, not specified | Yes | 1% isoflurane | 20 minute MCAO | BOLD fMRI, behavior, lesion vol, ADC (0 minutes/30 minutes/180 minutes/1 day/7 days/21 days post‐MCAO) |
| Kim et al | Sprague‐Dawley, male, adult | No | Alpha‐chloralose | 2 hour MCAO | BOLD and CBV fMRI (2 weeks post‐MCAO), lesion volume |
| Kim et al | Sprague‐Dawley, male, not specified | No | Alpha‐chloralose | 90 minute MCAO | BOLD and CBV fMRI (2 weeks post‐MCAO), lesion volume, effect of IV albumin. |
| Weber et al | Wistar, male, not specified | Yes | Medetomidine | 1 hour MCAO | BOLD fMRI, electrophysiology (2/7/14/28/49 days post‐MCAO) |
| Van Meer et al | Sprague‐Dawley, male, not specified | No | 1% isoflurane | 90 minute MCAO | RS‐fMRI, manganese‐enhanced MRI |
| Van Meer et al | Wistar, male, not specified | Yes | 1.8% isoflurane | 90 minute MCAO | RS‐fMRI (3, 7, 21, and 70 days post‐MCAO), lesion volume, manganese‐enhanced MRI, behavior |
| Van Meer et al | Sprague‐Dawley, male, young adult | Yes | 1% isoflurane | 90 minute MCAO | RS‐fMRI (3, 7, 21, 49, 70 says post‐MCAO), lesion volume, EEG, behavior |
| Shih et al | Sprague‐Dawley, male, adult | Yes | 1% isoflurane | 20 or 45 minute MCAO | CBV fMRI, electrophysiology (0/7/21 days post‐MCAO) |
| Lake et al | Sprague‐Dawley, male, adult | Yes | Propofol | Endothelin‐1 injection | CBF fMRI with hypercapnic stimulus, electrophysiology with forepaw stimulus (7 and 21 days post‐MCAO) |
| Lake et al | Sprague‐Dawley, male, adult | Yes | Propofol | Endothelin‐1 injection | CBF fMRI with hypercapnic stimulus (7 and 21 days post‐MCAO), effect of COX‐1 inhibitor |
| Shim et al | Sprague‐Dawley, not specified, adult | No | Alpha‐chloralose | 2 hour MCAO | BOLD fMRI, RS‐fMRI, Diffusion‐weighted MRI, lesion volume (6 months post‐MCAO) |